Watson gets OK for generic Daypro, Ritalin, Loestrin

Drug Store News, March 26, 2001

The Food and Drug Administration recently approved three abbreviated new drug applications from Watson: oxaprozin, methylphenidate hydrochloride and microgestin. Oxaprozin is the equivalent to G.D. Searle and Co.'s Daypro for osteoarthritis and rheumatoid arthritis. Methylphenidate hydrochloride is the generic equivalent to Novartis Pharmaceuticals' Ritalin for children with serious behavioral problems.

Microgestin tablets are the therapeutic equivalent to Parke Davis'/Pfizer's Loestrin, an oral contraceptive. Additionally, Watson and partner Genelabs Technologies are waiting for FDA review of Aslera (prasterone), an investigational lupus drug. The review is scheduled for April 19. If approved, Watson plans to launch the drug in summer 2001.

COPYRIGHT 2001 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale